RxDoctor Payments Data

Bhanumathi Krishnan, MD

Cardiovascular Disease · Fairfax, VANPI 1730281395

Payments from drug & device makers

$2,474in general payments, 2019–2025

Across 133 payments — averaging $18.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$477
  • Novartis$329
  • Amgen$300
  • Johnson & Johnson$217
  • Pfizer$161
  • Novo Nordisk$145
  • plus $846 from 22 others

What the payments were for

  • Food & beverage$2,474100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,474 in reported general payments places this provider in the 55th percentile of 548 cardiovascular disease providers in Virginia.

See all cardiovascular disease providers in Virginia

Medicare billing

Part B allowed, 2024
$385,054
Medicare patients
1,613
Services billed
4,381

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban287$358,746
XareltoRivaroxaban112$145,102
EntrestoSacubitril/Valsartan29$48,372
Repatha SureclickEvolocumab23$34,645
Metoprolol Succinate569$8,633
Ezetimibe189$5,433
Rosuvastatin Calcium354$5,359
Nebivolol Hcl76$3,916
Atorvastatin Calcium320$3,615
Diltiazem 24hr Er (Cd)Diltiazem Hcl61$3,393
Flecainide Acetate65$2,848
Amlodipine Besylate250$1,945
Amiodarone Hcl33$1,838
Losartan Potassium165$1,314
Telmisartan-HydrochlorothiazidTelmisartan/Hydrochlorothiazid23$1,192

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$161$358,746287 claims
Johnson & JohnsonXarelto$217$145,102112 claims
NovartisEntresto$329$48,37229 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 548 cardiovascular disease providers in Virginia.

Other cardiovascular disease in Fairfax

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →